286 related articles for article (PubMed ID: 27690385)
1. Small-Molecule Probes Reveal Esterases with Persistent Activity in Dormant and Reactivating Mycobacterium tuberculosis.
Tallman KR; Levine SR; Beatty KE
ACS Infect Dis; 2016 Dec; 2(12):936-944. PubMed ID: 27690385
[TBL] [Abstract][Full Text] [Related]
2. Profiling Esterases in Mycobacterium tuberculosis Using Far-Red Fluorogenic Substrates.
Tallman KR; Levine SR; Beatty KE
ACS Chem Biol; 2016 Jul; 11(7):1810-5. PubMed ID: 27177211
[TBL] [Abstract][Full Text] [Related]
3. Design of Selective Substrates and Activity-Based Probes for Hydrolase Important for Pathogenesis 1 (HIP1) from Mycobacterium tuberculosis.
Lentz CS; Ordonez AA; Kasperkiewicz P; La Greca F; O'Donoghue AJ; Schulze CJ; Powers JC; Craik CS; Drag M; Jain SK; Bogyo M
ACS Infect Dis; 2016 Nov; 2(11):807-815. PubMed ID: 27739665
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
5. Computational investigation of phytomolecules as resuscitation-promoting factor B (RpfB) inhibitors for clinical suppression of Mycobacterium tuberculosis dormancy reactivation.
Dwivedi VD; Arya A; Sharma T; Sharma S; Patil SA; Gupta VK
Infect Genet Evol; 2020 Sep; 83():104356. PubMed ID: 32438079
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
7. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
[TBL] [Abstract][Full Text] [Related]
8.
Nunes JES; Duque MA; de Freitas TF; Galina L; Timmers LFSM; Bizarro CV; Machado P; Basso LA; Ducati RG
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168746
[TBL] [Abstract][Full Text] [Related]
9. Design and Development of Mycobacterium tuberculosis Lysine ɛ-Aminotransferase Inhibitors for Latent Tuberculosis Infection.
Parthiban BD; Saxena S; Chandran M; Jonnalagadda PS; Yadav R; Srilakshmi RR; Perumal Y; Dharmarajan S
Chem Biol Drug Des; 2016 Feb; 87(2):265-74. PubMed ID: 26348876
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of hypothetical proteins of Mycobacterium tuberculosis with possible esterase/lipase signature: a cumulative in silico and in vitro approach.
Kumar A; Sharma A; Kaur G; Makkar P; Kaur J
J Biomol Struct Dyn; 2017 May; 35(6):1226-1243. PubMed ID: 27050490
[TBL] [Abstract][Full Text] [Related]
11. Latent Tuberculosis Infection (LTBI) and Its Potential Targets: An Investigation into Dormant Phase Pathogens.
Gutti G; Arya K; Singh SK
Mini Rev Med Chem; 2019; 19(19):1627-1642. PubMed ID: 31241015
[TBL] [Abstract][Full Text] [Related]
12. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the Thioesterase Activity of
Krieger IV; Yalamanchili S; Dickson P; Engelhart CA; Zimmerman MD; Wood J; Clary E; Nguyen J; Thornton N; Centrella PA; Chan B; Cuozzo JW; Gengenbacher M; Guié MA; Guilinger JP; Bienstock C; Hartl H; Hupp CD; Jetson R; Satoh T; Yeoman JTS; Zhang Y; Dartois V; Schnappinger D; Keefe AD; Sacchettini JC
ACS Infect Dis; 2024 May; 10(5):1561-1575. PubMed ID: 38577994
[TBL] [Abstract][Full Text] [Related]
17. Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures.
Batyrshina YR; Schwartz YS
Tuberculosis (Edinb); 2019 Jul; 117():7-17. PubMed ID: 31378272
[TBL] [Abstract][Full Text] [Related]
18. A mathematical representation of the development of Mycobacterium tuberculosis active, latent and dormant stages.
Magombedze G; Mulder N
J Theor Biol; 2012 Jan; 292():44-59. PubMed ID: 21968442
[TBL] [Abstract][Full Text] [Related]
19. Transition metal cation inhibition of Mycobacterium tuberculosis esterase RV0045C.
Bowles IE; Pool EH; Lancaster BS; Lawson EK; Savas CP; Kartje ZJ; Severinac L; Cho DH; Macbeth MR; Johnson RJ; Hoops GC
Protein Sci; 2021 Aug; 30(8):1554-1565. PubMed ID: 33914998
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
